Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Global biopharmaceutical firms Santen SA and Sydnexis have entered an exclusive licensing deal for a drug formulation that aims to treat progressive myopia.
BioLife will obtain all of the outstanding shares of Sexton that it doesn’t already own for $24 million in consideration for 506,382 newly issued shares of BioLife common stock.
The Trump White House removed Bright from his position at BARDA and reassigned him to a narrower role at the National Institutes of Health.
Mission Therapeutics and AbbVie announced their DUB inhibitor collaboration back in 2018.
Voyager’s primary focus will be on developing gene therapies for Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), and pre-clinical research in spinal muscular atrophy and diseases linked to GBA1 mutations.
Seagen forged an exclusive licensing agreement with China’s RemeGen Co., Ltd, to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC.
Oyster Point Pharma inked a license and collaboration deal with Ji Xing Pharmaceuticals to develop and market OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for dry eye disease in Great China.
The deal will give EQRx a pre-transaction enterprise value of $3.65 billion and an immediate $1.8 billion in cash that will be used to advance the development of the company’s pipeline.
Sierra will have access to AZD5153, a potent and selective BRD4 BET inhibitor, to initiate a study that combines the said component with momelotinib for treating patients with myelofibrosis.
Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers.